TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15358440
Drug: Open study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open study design with GH treatment for 6 months (Group II)
Study: 9582849
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy (two daily injections of a mixture of regular insulin/NPH)
Study: 7609279
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.15 mg of Somatropin per kilogram per day)
Study: 8189476
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of infusion (Control)
Study: 1977781
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg
Study: 1977781
Drug: Chlorpheniramine, 4
Normalized name: Chlorpheniramine, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine, 4 mg
Study: 416322
Drug: Clofibate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (1 g b.i.d.)
Study: 416322
Drug: Lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose placebo (1 g b.i.d.)
Study: 30567286
Drug: Moderate intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intake of total LC ω‐3 PUFA (approximately 0.5⁻1 g/day)
Study: 20537722
Drug: Manual Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Assisted Cognitive Therapy (MACT)
Study: 20537722
Drug: Manual Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Assisted Cognitive Therapy (MACT) + Therapeutic Assessment (TA)
Study: 30806492
Drug: Standard Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Behavioral Treatment (SBT)
Study: 7552878
Drug: Cyclosporine rinse
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine rinse (5 ml, 500 mg)
Study: 7552878
Drug: Placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rinse (5 ml)
Study: 2147909
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean dose 11 mg) + Atenolol (100 mg)
Study: 2147909
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) + Placebo
Study: 26099195
Drug: Zn alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn alone group (30 mg ZnSO4 daily)
Study: 26099195
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (30 mg ZnSO4 plus multivitamins)
Study: 26099195
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, 270 mg lactose)
Study: 21410693
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (15 minutes of daily bimanual training with a mirror for 3 weeks)
Study: 21410693
Drug: Bimanual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual training without a mirror (15 minutes daily for 3 weeks)
Study: 19281729
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral topotecan formulation (4 mg dose)
Study: 19281729
Drug: Current oral
Normalized name: black currant oil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current oral topotecan formulation (4 mg dose)
Study: 19281729
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral topotecan formulation (4 mg dose) in fed state
Study: 19281729
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral topotecan formulation (4 mg dose) in fasted state
Study: 15547701
Drug: oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral doxifluridine
Study: 15547701
Drug: intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 5-FU
Study: 15547701
Drug: intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of irinotecan
Study: 15547701
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of doxifluridine and irinotecan
Study: 2845349
Drug: RRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV vaccine (10^4 plaque-forming units)
Study: 28760801
Drug: Usual antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual antibiotic treatment with the addition of 8 L of polyethylene glycol (PEG) lavage via nasojejunal tube
Study: 28760801
Drug: Usual antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual antibiotic treatment
Study: 19081881
Drug: Plasma-spray and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-spray and small-bead coatings
Study: 17157114
Drug: Sumatriptan injection
Normalized name: sumatriptan Injection
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan injection 6 mg
Study: 14680204
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10 mg/kg after anaesthetic induction, on bypass, and after protamine at the end of bypass (group B)
Study: 14680204
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (group A)
Study: 8804799
Drug: Oral fluconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluconazole, 200 mg once daily
Study: 8804799
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B, 0.3 mg/kg
Study: 6541714
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B
Study: 1733187
Drug: Magnesium gluconate
Normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium gluconate 1 gm orally four times daily
Study: 6467800
Drug: Nifedipine (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (rectal infusion at a zero-order rate for 24 hr)
Study: 31437754
Drug: encorafenib 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Study: 31437754
Drug: encorafenib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: encorafenib 300 mg once daily
Study: 31437754
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg twice daily
Study: 29595687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GDPSF and thalidomide
Study: 25134860
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control (90-120 mg/dL)
Study: 25134860
Drug: Liberal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal glucose control (121-180 mg/dL)
Study: 9188352
Drug: No-treatment controls
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment controls
Study: 17592349
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg/kg
Study: 27052122
Drug: Methimazole therapy
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole therapy in subjects with TSH <1.0 μIU/mL
Study: 27052122
Drug: Observation (untreated)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation (untreated) in subjects with TSH <1.0 μIU/mL
Study: 27052122
Drug: Observation (untreated)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation (untreated) in subjects with TSH ≥1.0 μIU/mL
Study: 24581989
Drug: Daily recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily recombinant FSH
Study: 24581989
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa and Daily recombinant FSH
Study: 22415232
Drug: S-1 (80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses)
Study: 22415232
Drug: UFT/LV (UFT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (UFT, 300 mg m(‐2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses)
Study: 19458303
Drug: Medihoney Antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medihoney Antibacterial Wound Gel
Study: 17505376
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) group work
Study: 14678367
Drug: Enhanced patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced patient participation in treatment choice
Study: 14678367
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment protocol
Study: 9238887
Drug: Oral-B toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B toothbrush
Study: 2691573
Drug: Clovoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovoxamine (50 mg b.d. to 300 mg max)
Study: 2691573
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg b.d. to 30 mg max)
Study: 1105692
Drug: Laminaria tents
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria tents inserted 14-18 hr before PGF2alpha infusion
Study: 1105692
Drug: Laminaria tents
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria tents inserted at the same time as PGF2alpha infusion
Study: 28246338
Drug: Reference book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference book providing weight‐based precalculated doses
Study: 28246338
Drug: Card providing
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Card providing milligram‐per‐kilogram doses
Study: 25521275
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (1 µg) into tibialis anterior and erector spinae muscles and fasciae
Study: 25521275
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (1 µg)
Study: 25521275
Drug: Acidic buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic buffer injections (pH 4, 100 µl)
Study: 20878159
Drug: Docetaxel/cisplatin (DP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/cisplatin (DP) as first-line treatment
Study: 20878159
Drug: FOLFIRI as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI as first-line treatment
Study: 20878159
Drug: FOLFIRI as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI as second-line treatment
Study: 20878159
Drug: Docetaxel/cisplatin (DP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/cisplatin (DP) as second-line treatment
Study: 19885944
Drug: Far-infrared rays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far-infrared rays (FIR) applied to three acupuncture points (Nei-Kuan (PC6), Shenmen (HT7), Sanyinjiao (SP6)) for 15 minutes twice a week for four weeks
Study: 15277611
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil daily for 12 weeks
Study: 15277611
Drug: Open-label donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label donepezil (5 mg daily for 6 weeks, then 10 mg daily for 6 weeks)
Study: 8923850
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg, orally)
Study: 1404449
Drug: Beta-carotene (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (0, 15, 30, 45, or 60 mg daily for approximately 9 months)
Study: 3888229
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of fish oil (Maxepa)
Study: 3888229
Drug: 16 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/day of fish oil (Maxepa)
Study: 24097439
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (dual therapy)
Study: 24739593
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (monotherapy)
Study: 18854801
Drug: Natural plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural plant extracts for intimate hygiene (Salvia officinalis, Camomilla recutita, Thymus vulgaris) used once or twice a day for four weeks
Study: 16317014
Drug: Early chemotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early chemotherapy (MVP regimen: mitomycin C 8 mg/m2, vinblastine 6 mg/m2, cisplatin 50 mg/m2 or carboplatin AUC 5) every 3 weeks for up to six cycles
Study: 16317014
Drug: Delayed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed chemotherapy (initial best supportive care with chemotherapy added at time of symptomatic progression)
Study: 16317014
Drug: Early chemotherapy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early chemotherapy (MVP regimen)
Study: 8607237
Drug: Prostate-specific antigen
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) followed by transrectal ultrasonography of the prostate when PSA or DRE is abnormal
Study: 1750604
Drug: Inhaled nebulised
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulised fentanyl at 318 micrograms/ml
Study: 1750604
Drug: Inhaled nebulised
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulised fentanyl at 159 micrograms/ml
Study: 1750604
Drug: Inhaled nebulised
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulised fentanyl at 64 micrograms/ml
Study: 7128188
Drug: Bromocriptine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (15 mg per day)
Study: 7128188
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg per day)
Study: 19488607
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg bid for 90 days)
Study: 15832031
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of donepezil for 12 months
Study: 9846856
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg Zn as ZnSO4 daily in fruit juice, Monday to Friday for 6 months)
Study: 16823727
Drug: Insulin as
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin as part
Study: 10688392
Drug: Penciclovir cream
Normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penciclovir cream
Study: 1500686
Drug: human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: human lymphoblastoid interferon (ly‐IFN) at a dose of 5 MU/m2 i.m. three times a week for 6 months
Study: 21690287
Drug: Oral oseltamivir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oseltamivir
Study: 27548898
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Treatment (PST)
Study: 29794089
Drug: Interventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional therapy
Study: 22548767
Drug: Omeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (10 mg once daily)
Study: 22548767
Drug: Famotidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (10 mg twice daily)
Study: 22548767
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg three times daily)
Study: 22548767
Drug: Teprenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone (50 mg three times daily)
Study: 17274349
Drug: Continuous intervention
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intervention group (monthly educational campaign)
Study: 19787608
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) injection 2.5 mg 3-5 days before operation
Study: 19787608
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection before operation (noninjected group)
Study: 15545877
Drug: Tc-99m-labeled antigranulocyte
Normalized name: Technetium Tc 99m-labeled red blood cells
DrugBank: Technetium Tc-99m red blood cells (DB09493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc-99m-labeled antigranulocyte monoclonal antibody fragment Fab'2 (SMab, Leukoscan); 20 mCi (740 MBq) injected, scans obtained within 3 and 8 hours post-injection.
Study: 11727205
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IGI)
Study: 9450166
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) inhalation therapy (400 micrograms/day)
Study: 9450166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BDP inhalation therapy)
Study: 29322434
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (NAC) 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 hours
Study: 19860915
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (NAC)
Study: 29322434
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (NAC) and control group
Study: 26919554
Drug: Wraparound eyeglasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wraparound eyeglasses in addition to medical treatment (group 1, n = 39)
Study: 26919554
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (group 2, n = 31)
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 70 mg every 2 weeks
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 105 mg every 2 weeks
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 140 mg every 2 weeks
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 280 mg every 4 weeks
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 350 mg every 4 weeks
Study: 23141813
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 420 mg every 4 weeks
Study: 26638010
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day
Study: 20440092
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisolone administered immediately after surgery
Study: 20440092
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received Etorikoxib 120 mg 30 minutes before operation
Study: 18305291
Drug: Double-blind antidepressant
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind antidepressant treatment
Study: 12439162
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.51 mg/kg)
Study: 12439162
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (1.41 mg/kg)
Study: 2140489
Drug: Nicorandil 10
Normalized name: nicorandil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 10 mg
Study: 415330
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg of 95% ethanol
Study: 415330
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of delta9 tetrahydrocannabinol (THC)
Study: 415330
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of delta9 tetrahydrocannabinol (THC)
Study: 415330
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg of 95% ethanol together with 15 mg of THC
Study: 31072317
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Dual Task (EMDT) in combination with usual care
Study: 28125809
Drug: AmF/NaF/SnCl2 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/NaF/SnCl2 solution twice a day
Study: 28125809
Drug: AmF/NaF/SnCl2 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF/NaF/SnCl2 solution once a day
Study: 28125809
Drug: NaF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF solution (positive control, 500 ppm F‐, pH 4.5)
Study: 31355775
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg
Study: 25501988
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg and 600 mg
Study: 21875913
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel for 6 months
Study: 17023769
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 microg/kg in 10 minutes followed by an infusion rate of 0.2 microg/kg/hr)